Rituximab in chronic lymphocytic leukemia

Danelle F James1, Thomas J Kipps

  • 1Diversion of Hematology/Oncology, Moores UCSD Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0820, USA. dfjames@ucsd.edu

Advances in Therapy
|July 5, 2011
PubMed
Summary

Rituximab, a CD20-targeted therapy, shows limited activity alone in chronic lymphocytic leukemia (CLL). However, combining rituximab with chemotherapy significantly improves patient survival in CLL treatment.

Related Concept Videos